Tirzepatide and semaglutide are both GLP-1 receptor agonists available as compounded preparations when clinically appropriate. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal.
Tirzepatide vs Semaglutide at a Glance
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 receptor agonist |
| Commercial Brands | Mounjaro, Zepbound | Ozempic, Wegovy |
| Dosing Frequency | Weekly injection | Weekly injection |
| Compounded Option | Yes, patient-specific | Yes, patient-specific |
| FDA Approval | Yes (commercial brand only) | Yes (commercial brand only) |
How Providers Decide Between Them
A licensed provider considers multiple factors when discussing compounded GLP-1 options:
- Medical history and lab profile
- Tolerability and prior medication response
- Treatment goals and clinical context
- Documented clinical need for personalized formulation
Selection is individualized. There is no universal best choice.
What "Compounded" Means
Compounded preparations are patient-specific pharmacy formulations. They are not generic copies of commercial brands.
Compounded formulations differ from commercial brands. They are not interchangeable substitutes for FDA-approved products.
How TelosRX Handles Both
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and every compounded GLP-1 prescription is patient-specific.
- Step 1: Asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review and discussion of options.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded GLP-1 ships discreetly to your door.
Important Compliance Information
Compounded tirzepatide and semaglutide are not FDA-approved. They are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.